A phase 1, first in human, open-label, dose escalation and dose expansion study of TST005 in patients with locally advanced or metastatic solid

SITC 2022 Abstract TIP 771

Background

Anti-programmed death 1 / ligand 1 (PD-1/PD-L1) therapies have been established as standard treatment for multiple tumor types. However, the key challenge of these therapies is resistance caused by immunosuppressive factors in the tumor microenvironment (TME). TGF- β is a multi-functional cytokine that is involved in the tight regulation of either antitumor immunity or tumor immunosuppression. TGF-β promotes an immune exclusion TME thus renders PD-L1 blockade ineffective. Therefore, dual targeting PD-L1 and TGF- β represents a rational synergistic strategy to enhance clinical outcome relative to each agent alone.

TST005 is a novel bi-functional fusion protein combining a high affinity PD-L1 monoclonal antibody (mAb) in a fragment crystallizable (Fc) silenced immunoglobulin G1 (IgG1) backbone and a differentiated transforming growth factor beta (TGF-β) trap with improved stability. This study will investigate TST005's safety, tolerability and preliminary anti-tumor activity in solid tumors.

TST005 inhibits tumor growth in the mouse models




Figure 1. Tumor growth curve of TST005 and M7824 analog (mean ± S.E.M, n=10). A. In the MC38/hPD-L1 colorectal tumor model, At 10mg/kg, TST005 showed similar tumor inhibition compared to M7824 analog. B. In the EMT6/hPD-L1 breast tumor model, a model with higher TGF-β expression, at 30 mg/kg TST005 treatment showed better tumor inhibition compared to M7824 analog.

TST005 depletes plasma and tumor TGF-β1 in mouse model





Figure 2. The concentration of TGF-β1 in the MC38/hPD-L1 tumor–bearing mice treated with TST005 via single IV injection. Plasma (A) and tumor (B) TGF-β1 concentration were analyzed at pre-dose and 30min, 2h, 8h, 24h, 48h, D7 and D14, D21, D28 after treatment. TGF-B1 depletion in both plasma and tumor tissue was showed in a dose dependent manner with maximum depletion at 10mg/kg.

Anthony Tolcher¹, Nashat Gabrail², Minal Barve³, Xiaohua Wu⁴, Jian Zhang⁴, Michael Shi⁵, Chuan Qi⁵, Lei Chen⁵, Steven Yu⁵, Jenny Yao⁵, Jianming Wang⁵, Christopher T. Cavanaugh⁵ ¹NEXT Oncology, San Antonio, TX, USA; ²Gabrail Cancer, Canton, OH USA; ³Mary Crowley Cancer Research Centers, Dallas TX, USA; ⁴Fudan University Shanghai Cancer Center, Shanghai, P. R. China; ⁵Suzhou Transcenta Therapeutics Co., Ltd, Suzhou, Jiangsu, P. R. China

Methods and Study Design

TST005-1001 (NCT04958434) is a phase 1, first in human (FIH) open-label, multicenter trial that consists of a dose escalation phase in patients with advanced solid tumors who have failed prior therapy and a dose escalation phase in human papillomavirus (HPV) related malignancies not amenable to surgery and who have received prior standard therapy(ies).

Study Schema



Dose escalation phase

Comprises five dose cohorts: accelerated titration of 1 subject in the starting dose cohort (1 mg/kg), and then four dose cohorts (3 mg/kg, 10 mg/kg, 20 mg/kg, 30 mg/kg) following classic 3+3 design. No more than one prior immune checkpoint inhibitor (ICI) treatment is allowed for eligible subjects. **Dose expansion phase**

Up to 30 patients with locally advanced or metastatic HPV+ malignancies, including cervical cancers, P16+ Oropharyngeal cancers, and other tumors that are known HPV+, and who are ICI treatment naive will be enrolled to receive the recommended dose of TST005 treatment. Treatment

For both phases, subjects will receive TST005 intravenous infusion every 3 weeks (Q3W) until disease progression per RECIST v1.1 and/or immune RECIST or unacceptable toxicity. Subjects may continue to receive TST005 beyond RECIST v1.1 defined progression, per iRECIST, at the discretion of the Investigator.

Objectives

Dose escalation phase

Primary:

- subjects with previously treated advanced solid tumors Secondary:
- To characterize PK profile of TST005 in subjects with previously treated advanced solid tumors
- To characterize the immunogenicity of TST005

Dose expansion phase

Primary:

malignancies

Secondary:

To assess the efficacy of TST005 in subjects with locally advanced or metastatic HPV related malignancies by **RECIST V1.1**

To determine the maximum tolerated dose (MTD) or recommended Phase 2 dose(s) (RP2D) of TST005 in

To evaluate safety and tolerability of TST005 in subjects with locally advanced or metastatic HPV related

- Additional safety and tolerability
- malignancies

Exploratory (Both Phases)

- **TST005**

Inclusion Criteria

Dose escalation phase:

- that would confer clinical benefit.
- Evaluable disease per RECIST v1.1

Dose expansion phase:

- esophagus) that are known HPV positive.
- At least 1 measurable lesion per RECIST v1.1

Exclusion Criteria

Dose Escalation phase

Dose Expansion phase

- advanced setting.





To assess the PK of TST005 in subjects with locally advanced or metastatic HPV related

To assess the efficacy of TST005 by iRECIST and RECIST V1.1 (escalation phase) • To evaluate changes in disease biomarkers following treatment To explore correlations between biomarker expression, PK, PD and clinical readouts of

Major Eligibility Criteria

• Male or female patients aged 18 years or older.

Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.

• Adequate organ function per screening labs performed within 7 days of 1st dose

• Histologically or cytologically confirmed locally advanced or metastatic solid tumors.

• Tumor progression during or after prior therapy and for whom no standard therapy exists

• Histologically or cytologically confirmed diagnosis of locally advanced or metastatic HPV+ malignancies, including cervical cancers, P16+ Oropharyngeal cancers, anal cancers, vulvar, vaginal, penile, and squamous cell rectal cancers and other solid tumors (e.g., lung,

HPV related malignancy not amenable to potentially curative resection and have received prior standard of care therapy(ies) unless subject not eligible to receive standard therapy.

• Untreated or symptomatic central nervous system (CNS) metastases. • Active autoimmune diseases or history of autoimmune diseases that may relapse.

More than one prior checkpoint inhibitor therapies (approved or investigational) in the advanced setting. One prior checkpoint inhibitor therapy is allowed

• Received any prior checkpoint inhibitor therapies (approved or investigational) in the

• Prior treatment with any therapy target TGF-β or TGF-β receptors pathway.

Study Status

This study is ongoing at 4 sites in the US and China. As of the 24 Aug 2022, the first three dose cohorts has been completed the evaluation and no DLT was observed. Clinical trial information: NCT04958434. Study Sponsor: Suzhou Transcenta Therapeutics Co., Ltd.

pillomavirus; MTD = maximum tolerated dose; PD = pharmacodynamic PK = pharmacokinetics; Q3W = every 3 weeks; RP2D = recommended phase 2 dose: SAE = serious adverse event: